Recent Advances from the National Cancer Institute Alliance for Nanotechnology in Cancer

Farrell, Dorothy; Alper, Joe; Ptak, Krzystof; Panaro, Nicholas J.; Grodzinski, Piotr; Barker, Anna D.

doi:10.1021/nn100073g

Cited by 66 publications

(41 citation statements)

References 17 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, in the US, the National Cancer Institute (NCI) has launched several programmes over the past two decades to catalyse such research, including the Alliance for Nanotechnology in Cancer in 2004, where experts in nanotechnology have worked side by side with oncologists and clinicians to foster new approaches in cancer detection and treatment 206 . More recently, in 2009, the NCI also launched the Physical Sciences–Oncology Center (PS–OC) Network of 12 interdisciplinary teams, with the goal of incorporating the perspectives of physical scientists that might formulate and approach problems in a distinct way that provides complementary insights into cancer 207 .…”

Section: Future Directionsmentioning

confidence: 99%

Engineering and physical sciences in oncology: challenges and opportunities

2017

View full text Add to dashboard Cite

The principles of engineering and physics have been applied to oncology for nearly 50 years. Engineers and physical scientists have made contributions to all aspects of cancer biology, from quantitative understanding of tumour growth and progression to improved detection and treatment of cancer. Many early efforts focused on experimental and computational modelling of drug distribution, cell cycle kinetics and tumour growth dynamics. In the past decade, we have witnessed exponential growth at the interface of engineering, physics and oncology that has been fuelled by advances in fields including materials science, microfabrication, nanomedicine, microfluidics, imaging, and catalysed by new programmes at the National Institutes of Health (NIH), including the National Institute of Biomedical Imaging and Bioengineering (NIBIB), Physical Sciences in Oncology, and the National Cancer Institute (NCI) Alliance for Nanotechnology. Here, we review the advances made at the interface of engineering and physical sciences and oncology in four important areas: the physical microenvironment of the tumour and technological advances in drug delivery; cellular and molecular imaging; and microfluidics and microfabrication. We discussthe research advances, opportunities and challenges for integrating engineering and physical sciences with oncology to develop new methods to study, detect and treat cancer, and we also describe the future outlook for these emerging areas.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Engineering and physical sciences in oncology: challenges and opportunities

2017

View full text Add to dashboard Cite

show abstract

“…With many desirable properties, nanotechnology holds great potential in the areas of cancer diagnosis and therapy 1-3 . Various nanoparticles have been increasingly investigated for the targeted delivery of drugs especially those are poorly water-soluble yet potent antitumor drugs 4-6 .…”

Section: Introductionmentioning

confidence: 99%

Combined image guided monitoring the pharmacokinetics of rapamycin loaded human serum albumin nanoparticles with a split luciferase reporter

et al. 2016

View full text Add to dashboard Cite

Imaging guided techniques have been increasingly employed to investigate the pharmacokinetics (PK) and biodistribution of nanoparticle based drug delivery systems. In most cases, however, the PK profiles of drugs could vary significantly from that of drug delivery carriers upon administration in the blood circulation, which will complicate the interpretation of image findings. Herein we applied a genetically encoded luciferase reporter in conjunction of near infrared (NIR) fluorophores to investigate the respective PK profiles of drug and its carrier in a biodegradable drug delivery system. In this system, a prototype hydrophobic agent, rapamycin (Rapa), was encapsulated into human serum albumin (HSA) to form HSA Rapa nanoparticles, which were then labeled with Cy5 fluorophore to facilitate the fluorescence imaging of HSA carrier. Meanwhile, we employed transgenetic HN12 cells that were modified with a split luciferase reporter, whose bioluminescence function is regulated by Rapa, to reflect the PK profile of the encapsulated agent. It is interesting to uncover that there existed an obvious inconsistency of PK behaviors between HSA carrier and rapamycin in vitro and in vivo through near infrared fluorescence imaging (NIFRI) and bioluminescence imaging (BLI) after treatment with Cy5 labeled HSA Rapa. Nevertheless, HSA Rapa nanoparticles manifested a favorable in vivo PK and tumor suppression efficacy in a follow-up therapeutic study. The developed strategy of combining a molecular reporter and a fluorophore in this study could be extended to other drug delivery systems to provide profound insights for non-invasive real-time evaluation of PK profiles of drug-loaded nanoparticles in pre-clinical studies.

show abstract

“…Advances in nanotechnology, especially graphene based materials have led to the generation of more sensitive and non-invasive biosensors for medical diagnosis. 1-6 …”

Section: Introductionmentioning

confidence: 99%

Reduced graphene oxide decorated with gold nanoparticle as signal amplification element on ultra-sensitive electrochemiluminescence determination of caspase-3 activity and apoptosis using peptide based biosensor

Khalilzadeh¹,

Shadjou²,

Afsharan³

et al. 2016

Bioimpacts

View full text Add to dashboard Cite

Introduction:Growing demands for ultrasensitive biosensing have led to the development of numerous signal amplification strategies. In this report, a novel electrochemiluminescence (ECL) method was developed for the detection and determination of caspase-3 activity based on reduced graphene oxide sheets decorated by gold nanoparticles as signal amplification element and horseradish peroxidase enzyme (HRP) as ECL intensity enhancing agent. Methods: The ECL intensity of the luminol was improved by using the streptavidin coated magnetic beads and HRP in the presence of hydrogen peroxide. The cleavage behavior of caspase-3 was characterized by cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) techniques using biotinylated peptide (DEVD containing peptide) which was coated on reduced graphene oxide decorated with gold nanoparticle. The surface modification of graphene oxide was successfully confirmed by FTIR, UV-vis and x-ray spectroscopy. Results: ECL based biosensor showed that the linear dynamic range (LDR) and the lower limit of quantification (LLOQ) were 0.5-100 and 0.5 femtomolar (fM), respectively. Finally, the performance of the engineered peptide based biosensor was validated in the A549 cell line as real samples. Conclusion: The prepared peptide based biosensor could be considered as an excellent candidate for early detection of apoptosis, cell turnover, and cancer related diseases.

show abstract

Recent Advances from the National Cancer Institute Alliance for Nanotechnology in Cancer

Cited by 66 publications

References 17 publications

Engineering and physical sciences in oncology: challenges and opportunities

Engineering and physical sciences in oncology: challenges and opportunities

Combined image guided monitoring the pharmacokinetics of rapamycin loaded human serum albumin nanoparticles with a split luciferase reporter

Reduced graphene oxide decorated with gold nanoparticle as signal amplification element on ultra-sensitive electrochemiluminescence determination of caspase-3 activity and apoptosis using peptide based biosensor

Contact Info

Product

Resources

About